-
Tumor-promoting and pro-angiogenic effects of roxarsone via VEGFR2/PLCγ/PKC signaling.
Chemico-biological interactions 20180825
-
Why are most phospholipidosis inducers also hERG blockers?
Archives of toxicology 20171201
-
The aryl hydrocarbon receptor is required for induction of p21cip1/waf1 expression and growth inhibition by SU5416 in hepatoma cells.
Oncotarget 20170411
-
Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension.
Circulation research 20150828
-
Caveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species.
Free radical biology & medicine 20140801
-
NADPH oxidase 4 is expressed in pulmonary artery adventitia and contributes to hypertensive vascular remodeling.
Arteriosclerosis, thrombosis, and vascular biology 20140801
-
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorganic & medicinal chemistry letters 20130801
-
A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery.
The Biochemical journal 20130415
-
Resveratrol ameliorates high-glucose-induced hyperpermeability mediated by caveolae via VEGF/KDR pathway.
Genes & nutrition 20130301
-
Vitamin D improves the angiogenic properties of endothelial progenitor cells.
American journal of physiology. Cell physiology 20121101
-
Leptin induces tube formation in first-trimester extravillous trophoblast cells.
European journal of obstetrics, gynecology, and reproductive biology 20120901
-
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Bioorganic & medicinal chemistry 20120715
-
VEGF regulates antidepressant effects of lamotrigine.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120601
-
N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.
Bioorganic & medicinal chemistry 20120401
-
Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations.
Journal of molecular graphics & modelling 20120201
-
N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.
Bioorganic & medicinal chemistry 20120115
-
Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization.
Ophthalmic research 20120101
-
Normalization of the lymph node T cell stromal microenvironment in lpr/lpr mice is associated with SU5416-induced reduction in autoantibodies.
PloS one 20120101
-
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
PloS one 20120101
-
SU5416, a VEGF receptor inhibitor and ligand of the AHR, represents a new alternative for immunomodulation.
PloS one 20120101
-
Unexpected neuronal protection of SU5416 against 1-Methyl-4-phenylpyridinium ion-induced toxicity via inhibiting neuronal nitric oxide synthase.
PloS one 20120101
-
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Current cancer drug targets 20111101
-
Clinical experience with antiangiogenic therapy in leukemia.
Current cancer drug targets 20111101
-
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
Nature biotechnology 20111101
-
[The effects of VEGF-R inhibitor on podocytopathy of rats with type I diabetic nephropathy].
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20110901
-
Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1.
Developmental cell 20110816
-
SU5416 and EGCG work synergistically and inhibit angiogenic and survival factors and induce cell cycle arrest to promote apoptosis in human malignant neuroblastoma SH-SY5Y and SK-N-BE2 cells.
Neurochemical research 20110801
-
Peptide-directed highly selective targeting of pulmonary arterial hypertension.
The American journal of pathology 20110601
-
Virtual screening and further development of novel ALK inhibitors.
Bioorganic & medicinal chemistry 20110515
-
Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism.
American journal of physiology. Heart and circulatory physiology 20110401
-
Suppression of choroidal neovascularization by intravitreal injection of liposomal SU5416.
Archives of ophthalmology (Chicago, Ill. : 1960) 20110301
-
The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension.
Respiration; international review of thoracic diseases 20110101
-
SU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.
Molecular vision 20110101
-
A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors.
PloS one 20110101
-
Angiogenesis but not neurogenesis is critical for normal learning and memory acquisition.
Neuroscience 20101124
-
Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633.
Cancer letters 20101001
-
Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
American journal of respiratory and critical care medicine 20100901
-
Anti-vascular endothelial growth factor treatment in combination with chemotherapy delays hematopoietic recovery due to decreased proliferation of bone marrow hematopoietic progenitor cells.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20100901
-
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
Bioorganic & medicinal chemistry 20100715
-
Novel pyrazole derivatives: synthesis and evaluation of anti-angiogenic activity.
Bioorganic & medicinal chemistry 20100615
-
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.
Bioorganic & medicinal chemistry letters 20100515
-
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
Bioorganic & medicinal chemistry 20100515
-
TSU-16, (Z)-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone, is a potent activator of aryl hydrocarbon receptor and increases CYP1A1 and CYP1A2 expression in human hepatocytes.
Chemico-biological interactions 20100415
-
CREB activation mediates VEGF-A's protection of neurons and cerebral vascular endothelial cells.
Journal of neurochemistry 20100401
-
Vascular endothelial growth factor is involved in mediating increased de novo hippocampal neurogenesis in response to traumatic brain injury.
Journal of neurotrauma 20100301
-
Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
Journal of medicinal chemistry 20100225
-
Stimulation of sphingosine 1-phosphate signaling as an alveolar cell survival strategy in emphysema.
American journal of respiratory and critical care medicine 20100215
-
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors.
Bioorganic & medicinal chemistry 20100215
-
Vascular endothelial growth factor receptor-2 inhibition promotes cell death and limits endothelial cell proliferation in a neonatal rodent model of stroke.
Stroke 20100201
-
ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice.
Gastroenterology 20100101
-
Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 20100101
-
Synthesis and radiopharmacological investigation of 3-[4'-[(18)F]fluorobenzylidene]indolin-2-one as possible tyrosine kinase inhibitor.
Bioorganic & medicinal chemistry 20091115
-
Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.
Experimental eye research 20091101
-
Design, synthesis, and X-ray crystal structures of 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors.
Bioorganic & medicinal chemistry 20091015
-
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
Nature chemical biology 20091001
-
Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats.
American journal of physiology. Regulatory, integrative and comparative physiology 20090701
-
Genetic evidence for a noncanonical function of seryl-tRNA synthetase in vascular development.
Circulation research 20090605
-
VEGF and angiogenesis in acute and chronic MOG((35-55)) peptide induced EAE.
Journal of neuroimmunology 20090430
-
Oral administration of pyrrolidine dithiocarbamate (PDTC) inhibits VEGF expression, tumor angiogenesis, and growth of breast cancer in female mice.
Cancer biology & therapy 20090315
-
VEGFR1 receptor tyrosine kinase localization to the Golgi apparatus is calcium-dependent.
Experimental cell research 20090310
-
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors.
Pediatric blood & cancer 20090201
-
VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
International immunopharmacology 20090101
-
Ligation or cross-linking of CD40 has different effects on AGS gastric cancer cells.
Cellular immunology 20090101
-
Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Cancer letters 20081108
-
Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib.
British journal of cancer 20080520
-
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
Bioorganic & medicinal chemistry 20080515
-
Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 20080401
-
Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants.
American journal of physiology. Lung cellular and molecular physiology 20080101
-
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
Journal of translational medicine 20080101
-
Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome.
Human reproduction update 20080101
-
Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase.
Japanese journal of ophthalmology 20080101
-
Development of an intravenous formulation of SU010382 (prodrug of SU5416, an anti-angiogenesis agent).
PDA journal of pharmaceutical science and technology 20080101
-
VEGF modulation of retinal pigment epithelium resistance.
Experimental eye research 20071201
-
Role of NADPH oxidase and ANG II in diabetes-induced retinal leukostasis.
American journal of physiology. Regulatory, integrative and comparative physiology 20071001
-
Effect of chemical stabilizers of hypoxia-inducible factors on early lung development.
American journal of physiology. Lung cellular and molecular physiology 20070901
-
Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate.
Oncogene 20070531
-
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.
Investigational new drugs 20070401
-
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.
Circulation research 20070330
-
Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles.
Bioorganic & medicinal chemistry letters 20070315
-
Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis.
Anti-cancer drugs 20070301
-
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer chemotherapy and pharmacology 20070201
-
[Clinical importance of angiogenesis and angiogenic factors in oncohematology].
Wiadomosci lekarskie (Warsaw, Poland : 1960) 20070101
-
Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.
Leukemia & lymphoma 20061201
-
Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice.
Journal of the American Society of Nephrology : JASN 20061101
-
Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension.
American journal of physiology. Lung cellular and molecular physiology 20061001
-
An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
The Journal of clinical endocrinology and metabolism 20061001
-
Structure-activity-relationship studies of conformationally restricted analogs of combretastatin A-4 derived from SU5416.
Bioorganic & medicinal chemistry 20061001
-
Inhibition of RET tyrosine kinase by SU5416.
Journal of molecular endocrinology 20061001
-
[Recent advances in the study of pharmacological activities and solid-phase synthesis of indoles and their analogues].
Yao xue xue bao = Acta pharmaceutica Sinica 20060801
-
Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo.
International journal of cancer 20060715
-
A phase I study with oral SU5416 in patients with advanced solid tumors: a drug inducing its clearance.
Investigational new drugs 20060701
-
VEGF-C promotes survival in podocytes.
American journal of physiology. Renal physiology 20060701
-
Vascular endothelial growth factor and hepatocyte regeneration in acetaminophen toxicity.
American journal of physiology. Gastrointestinal and liver physiology 20060701
-
Anti-angiogenic and anti-HER therapy.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20060701
-
Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase.
Journal of medicinal chemistry 20060601
-
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
-
Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
American journal of clinical oncology 20060401
-
Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.
Toxicology in vitro : an international journal published in association with BIBRA 20060301
-
Emerging Flt3 kinase inhibitors in the treatment of leukaemia.
Expert opinion on emerging drugs 20060301
-
A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
Japanese journal of clinical oncology 20060201
-
Clinical implications for vascular endothelial growth factor in the lung: friend or foe?
Respiratory research 20060101
-
Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.
Bioorganic & medicinal chemistry letters 20051215
-
Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
Cancer chemotherapy and pharmacology 20051201
-
Nerve growth factor-induced migration of endothelial cells.
The Journal of pharmacology and experimental therapeutics 20051201
-
A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
British journal of cancer 20051017
-
Functional CT for quantifying tumor perfusion in antiangiogenic therapy in a rat model.
Radiology 20051001
-
Indolin-2-ones with high in vivo efficacy in a model for multiple sclerosis.
Journal of medicinal chemistry 20050825
-
Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050701
-
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Cancer research 20050615
-
[Potential pharmacological treatments for diabetic retinopathy].
Nihon rinsho. Japanese journal of clinical medicine 20050601
-
[Medications for diabetic macular edema].
Nihon rinsho. Japanese journal of clinical medicine 20050601
-
Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family.
Clinical cancer research : an official journal of the American Association for Cancer Research 20050315
-
C-kit as a target in the treatment of acute myelogenous leukemia.
Current hematology reports 20050101
-
Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation.
Journal of immunology (Baltimore, Md. : 1950) 20050101
-
Emphysema: an autoimmune vascular disease?
Proceedings of the American Thoracic Society 20050101
-
Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
International journal of radiation oncology, biology, physics 20041115
-
SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway.
Biochemical and biophysical research communications 20041112
-
c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism.
Cancer research 20040915
-
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
European journal of pharmacology 20040913
-
Vascular endothelial growth factor in diabetes induced early retinal abnormalities.
Diabetes research and clinical practice 20040901
-
Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 20040901
-
SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
Journal of hepatology 20040801
-
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 20040701
-
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20040615
-
Determination of SU5416, a novel angiogenesis inhibitor, in human plasma by liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040605
-
The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1).
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040501
-
The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation.
The American journal of pathology 20040501
-
[Lung cancer: molecular targeting therapy].
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society 20040501
-
New cancer therapeutics: target-specific in, cytotoxics out?
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401
-
Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 20040401
-
N-acetylcysteine treatment protects against VEGF-receptor blockade-related emphysema.
COPD 20040401
-
Antiangiogenic therapy for von Hippel-Lindau disease.
JAMA 20040225
-
Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20040201
-
Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
Cancer chemotherapy and pharmacology 20040101
-
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20040101
-
Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
Urologic oncology 20040101
-
Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Cancer research 20031215
-
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 20031015
-
Human NADPH-cytochrome p450 reductase overexpression does not enhance the aerobic cytotoxicity of doxorubicin in human breast cancer cell lines.
Cancer research 20031015
-
The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide adenine dinucleotide phosphate oxidase activity.
Cancer research 20031015
-
Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor.
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20030901
-
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 20030801
-
Research retreat: Pfizer eliminates Sugen, shrinks cancer infrastructure.
Journal of the National Cancer Institute 20030716
-
Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade.
American journal of respiratory cell and molecular biology 20030701
-
Treatment of von Hippel-Lindau retinal hemangioblastoma by the vascular endothelial growth factor receptor inhibitor SU5416 is more effective for associated macular edema than for hemangioblastomas.
American journal of ophthalmology 20030701
-
SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Cancer research 20030701
-
SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis.
Molecular cancer therapeutics 20030701
-
Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models.
The Journal of pharmacology and experimental therapeutics 20030601
-
Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030601
-
Potential inhibitors of angiogenesis. Part I: 3-(imidazol-4(5)-ylmethylene)indolin-2-ones.
Journal of enzyme inhibition and medicinal chemistry 20030601
-
Potential inhibitors of angiogenesis. Part II: 3-(azolylmethylene)-2,3-dihydrobenzo[b]furan-2-ones.
Journal of enzyme inhibition and medicinal chemistry 20030601
-
Vascular endothelial growth factor (VEGF) receptor-2 signaling mediates VEGF-C(deltaNdeltaC)- and VEGF-A-induced angiogenesis in vitro.
Experimental cell research 20030501
-
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
The Journal of clinical investigation 20030501
-
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 20030501
-
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 20030415
-
[From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
Il Giornale di chirurgia 20030401
-
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.
Journal of medicinal chemistry 20030327
-
Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse.
Reproduction (Cambridge, England) 20030301
-
Improved effect of an antiangiogenic tyrosine kinase inhibitor (SU5416) by combinations with fractionated radiotherapy or low molecular weight heparin.
Neoplasia (New York, N.Y.) 20030301
-
[Perspectives on the oncologist pharmacopoeia].
Bulletin du cancer 20030101
-
Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification.
BMC cancer 20030101
-
Flt3 in acute myelogenous leukemia: biology, prognosis, and therapeutic implications.
Medical oncology (Northwood, London, England) 20030101
-
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.
Journal of medicinal chemistry 20021219
-
Synthetic lethality: killing cancer with cancer.
Journal of the National Cancer Institute 20021120
-
Zebrafish: a preclinical model for drug screening.
Assay and drug development technologies 20021101
-
SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase.
Blood 20021015
-
Inhibitors of the vascular endothelial growth factor receptor.
Hematology/oncology clinics of North America 20021001
-
New drugs in acute myeloid leukemia.
Current oncology reports 20020901
-
Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416.
Ophthalmology 20020901
-
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 20020901
-
Targeting vascular endothelial growth factor in colorectal cancer.
Oncology (Williston Park, N.Y.) 20020801
-
A novel dihydroxanthenone, AGI-B4 with inhibition of VEGF-induced endothelial cell growth.
The Journal of antibiotics 20020701
-
Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
The Journal of surgical research 20020601
-
Orthogonal polarisation spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo: a validation study.
British journal of cancer 20020520
-
CHS 828 inhibits neuroblastoma growth in mice alone and in combination with antiangiogenic drugs.
Pediatric research 20020501
-
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
The Journal of biological chemistry 20020419
-
Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315
-
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315
-
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020315
-
Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Molecular cancer therapeutics 20020301
-
SU5416 delays wound healing through inhibition of TGF-beta 1 activation.
Cancer biology & therapy 20020101
-
New chemotherapeutic agents: update of major chemoradiation trials in solid tumors.
Oncology 20020101
-
Comparative study of isoflavone, quinoxaline and oxindole families of anti-angiogenic agents.
Angiogenesis 20020101
-
Combining antiangiogenic agents with metronomic chemotherapy enhances efficacy against late-stage pancreatic islet carcinomas in mice.
Cold Spring Harbor symposia on quantitative biology 20020101
-
Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma.
Angiogenesis 20020101
-
Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.
Clinical cancer research : an official journal of the American Association for Cancer Research 20011001
-
Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival.
The Kobe journal of medical sciences 20010801
-
Simultaneous determination of SU5416 and its phase I and phase II metabolites in rat and dog plasma by LC/MS/MS.
Journal of pharmaceutical and biomedical analysis 20010701
-
Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.
Blood 20010701
-
Magnetic resonance imaging of ethyl-nitrosourea-induced rat gliomas: a model for experimental therapeutics of low-grade gliomas.
Journal of neuro-oncology 20010701
-
Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Cancer research 20010501
-
Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010501
-
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Gan to kagaku ryoho. Cancer & chemotherapy 20010501
-
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Blood 20010301
-
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
The oncologist 20010101
-
Endothelial survival factors as targets for antineoplastic therapy.
Cancer journal (Sudbury, Mass.) 20010101
-
Role of angiogenesis inhibitors in acute myeloid leukemia.
Cancer journal (Sudbury, Mass.) 20010101
-
Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
Journal of medicinal chemistry 20000713
-
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Journal of medicinal chemistry 20000615
-
Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Journal of medicinal chemistry 19991216
-
Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Journal of medicinal chemistry 19980702